Investigators report a 24-month recurrence-free survival rate of 82% with the use of intravesical gemcitabine/docetaxel following complete transurethral resection of bladder tumor.
Study reveals factors that could distinguish PSA bounce from biochemical recurrence after stereotactic body radiation therapy for prostate cancer.
While socioeconomic disparities are evident, survival differences between racial groups persist after RCC diagnosis.
Men with a history of priapism had increased risk for pulmonary embolism compared with men with other forms of sexual dysfunction.
Immune checkpoint inhibitors may be more beneficial than tyrosine kinase inhibitors for patients undergoing cytoreductive nephrectomy for metastatic renal cell carcinoma.
Rezūm therapy significantly improved symptoms, urinary flow, and quality of life in men across a wide range of prostate sizes, data show.
Grade group 1 prostate cancers declined as a proportion of all prostate cancers.
Following the approval of cabazitaxel in 2010, there are now an unprecedented number of life-prolonging therapies for men with metastatic disease.
The procedure is now performed in one-third of all surgeries for benign prostatic hyperplasia, a study found.
Study characterized patient-reported delays in care of prostate cancer and bladder cancer at the national level.
